@article{9adac5b600464a54a60305fe4e6bcb61,
title = "Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B",
author = "Surbhi Saini and Croteau, {Stacy E.} and Horling, {Frank M.} and Dunn, {Amy L.}",
note = "Funding Information: ALD reports grants, personal fees and non‐financial support from Bayer; grants and personal fees from Bioverativ; grants, personal fees and non‐financial support from CSL Behring; grants, personal fees and non‐financial support from Pfizer; grants, personal fees and non‐financial support from Shire; personal fees and non‐fi‐ nancial support from Medscape; grants, personal fees and non‐fi‐ nancial support from Hema Biologics; grants from Alnylam; grants from Octapharma; personal fees and non‐financial support from NovoNordisk; other from LittleSeed Inc. SEC reports institutional research funds from Pfizer, Spark Therapeutics, Genentech, and Boehringer Ingelheim, and consulting fees or honoraria from Bayer, Biomarin, Bioveritiv, Catalyst Biosciences, CSL‐Behring, Genentech, Novo Nordisk, and Octapharma. FMH was an em‐ ployee of Shire until 06/2018. SS declared that there is no conflict of interest.",
year = "2019",
month = mar,
doi = "10.1111/hae.13696",
language = "English (US)",
volume = "25",
pages = "e126--e129",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "2",
}